254435-95-5
254435-95-5 structure
- Name: Alisporivir
- Chemical Name: Alisporivir
- CAS Number: 254435-95-5
- Molecular Formula: C63H113N11O12
- Molecular Weight: 1216.638
- Catalog: Signaling Pathways Anti-infection HCV
- Create Date: 2018-05-28 16:48:22
- Modify Date: 2024-01-02 20:33:58
-
Alisporivir (DEB-025) is a cyclophilin inhibitor molecule with potent anti-hepatitis C virus (HCV) activity.
| Name | Alisporivir |
|---|---|
| Synonyms |
(3S,6S,9S,12R,15S,18S,21S,24S,27R,30S,33S)-25,30-Diethyl-33-[(1R,2R,4E)-1-hydroxy-2-methyl-4-hexen-1-yl]-6,9,18-triisobutyl-3,21,24-triisopropyl-1,4,7,10,12,15,19,27,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone
VBP9099AA6 Alisporivir Debio 025 DEB025 1,4,7,10,13,16,19,22,25,28,31-Undecaazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone, 25,30-diethyl-33-[(1R,2R,4E)-1-hydroxy-2-methyl-4-hexen-1-yl]-1,4,7,10,12,15,19,27,28-nonamethyl-3,21,24-tris(1-methylethyl)-6,9,18-tris(2-methylpropyl)-, (3S,6S,9S,12R,15S,18S,21S,24S,27R,30S,33S)- UNIL-025 |
| Description | Alisporivir (DEB-025) is a cyclophilin inhibitor molecule with potent anti-hepatitis C virus (HCV) activity. |
|---|---|
| Related Catalog | |
| In Vitro | DEB025 binds to CypA, a peptidyl-prolyl cis-trans isomerase which is a crucial cofactor for HCV replication[1]. Alisporivir (Debio-025) is an analogue of cyclosporine A and represents the prototype of a new class of non-immunosuppressive cyclophilin inhibitors. Alisporivir prevents HCV protein-mediated collapse of the respiration-driven mitochondrial membrane potential. Alisporivir prevents HCV protein-mediated mitochondrial dysfunction outside the context of apoptosis, calcium overload, production of ROS, dysfunction[2]. In cell culture models, low-micromolar doses of alisporivir block SARS-CoV and MERS-CoV replication. Combination treatment with alisporivir and ribavirin increases the anti-MERS-CoV activity in cell culture[3]. Alisporivir pretreatment stimulates antigen presentation by hepatoma target cells, leading to enhancement of antigen-specific CD8+ T cell activation by 40%. Alisporivir induces an increase of MHC-I and beta-2 microglobulin on the surface of several cell lines[4]. |
| In Vivo | Combination treatment with alisporivir and ribavirin does not protect against SARS-CoV infection in a mouse model[3]. |
| Cell Assay | Alisporivir is prepared in DMSO at 4 mM and diluted in cell culture medium at the indicated concentrations (0.1, 0.2, 0.3, 0.4, 0.5 μM). UHCV-32 and UHCVcon-57.3 are U-2 OS human osteosar coma-derived cell lines inducibly expressing the entire open reading frame derived from the HCV H77 prototype and consensus clones, respectively. Cell viability is measured by trypan blue exclusion analysis. HCV protein expression in these cells is induced by withdrawal of tetracycline from the culture medium. The effect of tetracycline on the naive U2 OS cell line is tested measuring mitochondria-related respiration and reactive oxygen species (ROS) production, which remains unchanged[2]. |
| References |
| Density | 1.0±0.1 g/cm3 |
|---|---|
| Boiling Point | 1294.2±65.0 °C at 760 mmHg |
| Molecular Formula | C63H113N11O12 |
| Molecular Weight | 1216.638 |
| Flash Point | 736.5±34.3 °C |
| Exact Mass | 1215.857056 |
| LogP | 3.84 |
| Vapour Pressure | 0.0±0.6 mmHg at 25°C |
| Index of Refraction | 1.467 |
| Storage condition | 2-8℃ |